Top Page
Neurotech International
(Sydney:NTI)
Neurotech International (NTI) vs. iShares MSCI Australia ETF (EWA)
Neurotech International Business Overview & Revenue Model
Neurotech International Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 80.48K | 1.96K | 5.96K | 38.26K | 206.14K | 77.37K |
| Gross Profit | -7.84M | -5.87K | 4.21K | -535.21K | -238.72K | -546.40K |
| EBITDA | -11.94M | -8.24M | -8.98M | -3.36M | 0.00 | -1.21M |
| Net Income | -11.79M | -5.07M | -7.79M | -3.36M | -7.43M | -1.71M |
Balance Sheet | ||||||
| Total Assets | 6.43M | 12.21M | 5.31M | 2.02M | 5.01M | 80.81K |
| Cash, Cash Equivalents and Short-Term Investments | 5.96M | 11.63M | 5.03M | 1.90M | 4.83M | 12.36K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.20K |
| Total Liabilities | 695.14K | 314.70K | 1.35M | 592.98K | 1.14M | 727.10K |
| Stockholders Equity | 5.74M | 11.90M | 3.96M | 1.43M | 3.86M | -646.29K |
Cash Flow | ||||||
| Free Cash Flow | -9.82M | -4.60M | -6.32M | -2.96M | -2.32M | -682.83K |
| Operating Cash Flow | -9.82M | -4.60M | -6.32M | -2.96M | -2.32M | -682.83K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -3.21K | 0.00 | 0.00 |
| Financing Cash Flow | 11.30M | 11.19M | 9.45M | 26.40K | 7.13M | 220.51K |
Neurotech International Technical Analysis
Neurotech International Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ¥342.56B | 10.47 | -2.86% | 2.57% | 11.81% | -7.17% | |
47 Neutral | AU$8.98M | ― | -375.15% | ― | -59.01% | 17.13% | |
45 Neutral | AU$16.99M | ― | -199.38% | ― | 271.05% | 42.55% | |
43 Neutral | AU$19.94M | ― | -223.80% | ― | -84.64% | -106.90% | |
41 Neutral | AU$10.76M | ― | -61.15% | ― | 35.63% | 18.55% | |
39 Underperform | AU$9.43M | ― | -98.08% | ― | -7.44% | 30.34% | |
38 Underperform | AU$8.54M | ― | -191.40% | ― | ― | 19.74% |
Neurotech International Corporate Events
Neurotech International Ltd has achieved significant milestones in its clinical and corporate activities. The European Commission granted Orphan Drug Designation for NTI164, its lead drug candidate for Rett Syndrome, offering potential market exclusivity and regulatory incentives in the EU. Additionally, a Phase I/II clinical trial for NTI164 in Autism Spectrum Disorder showed promising results, supporting its efficacy and safety. The company also signed a development agreement with RH Pharma to enhance its product development capabilities and expand into new markets. Furthermore, Neurotech welcomed Dr. Anthony Filippis as its new Managing Director and CEO, and received a $2.44 million R&D tax incentive refund from the Australian government.
Neurotech International Limited has updated its Trading Policy in compliance with ASX Listing Rule 12.10. This revision aims to guide the company’s Key Management Personnel in the sale and purchase of securities, emphasizing the importance of avoiding insider trading. The updated policy reflects the company’s commitment to ethical trading practices and aligns with legal requirements, potentially impacting the company’s governance and stakeholder trust.
Neurotech International Limited announced the issuance of ordinary fully paid shares without disclosure to investors under Part 6D.2 of the Corporations Act. The company has complied with relevant provisions of the Corporations Act and confirmed there is no excluded information that investors would expect in a disclosure document, indicating transparency and adherence to regulatory standards.
Neurotech International Ltd. has announced the issuance of 7,500,000 fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure and potentially improve its market positioning, providing opportunities for growth and increased stakeholder value.
Neurotech International Limited has announced the resignation of Thomas Duthy from its board of directors, effective April 1, 2025. Duthy held significant interests in the company through entities such as Emmirato Pty Ltd and CIPA Investments Pty Ltd, including 340,000 ordinary shares and 20 million unlisted options. His departure may impact the company’s strategic direction and stakeholder relations, given his substantial holdings and influence.
Neurotech International Limited announced the resignation of Dr. Thomas Duthy as an Executive Director, effective immediately, as he pursues other business interests. Dr. Duthy played a crucial role in the company’s clinical and corporate development, including raising $19 million in capital. His departure marks a significant transition for Neurotech as it continues to advance its drug development efforts in pediatric neurological disorders.
Neurotech International Limited has announced that the European Commission has granted Orphan Drug Designation for its lead candidate, NTI164, for the treatment of Rett Syndrome. This designation provides the company with several development incentives, including market exclusivity in the EU, reduced regulatory fees, and access to EU research funding. This milestone complements a similar designation by the US FDA, enhancing Neurotech’s position in major global markets and supporting its mission to address significant unmet needs in the treatment of rare neurological disorders.
Neurotech International Ltd has retracted a statement from its recent presentation at the NWR Virtual Healthcare Conference regarding its ‘Market Opportunity’ claims. The company acknowledged it lacked a reasonable basis for the statement and advised investors not to rely on it for making investment decisions. This retraction may impact investor confidence and the company’s market positioning.
Neurotech International Limited announced the publication of its Phase I/II autism spectrum disorder (ASD) clinical trial results in the journal Advances in Complimentary and Alternative Medicine. The study, led by Professor Michael Fahey, demonstrated that the company’s cannabinoid drug therapy, NTI164, is safe and well-tolerated in children with ASD, showing significant efficacy in improving disruptive behaviors and reducing anxiety. This publication marks an important step in establishing scientific evidence for Neurotech’s programs, potentially enhancing patient safety and health outcomes in the long term.
Neurotech International Limited announced its participation in the NWR Virtual Healthcare Conference, where CEO Dr. Anthony Filippis will present the company’s refined strategy aimed at accelerating revenue generation and commercialization opportunities. The strategy includes advancing regulatory approvals in Australia and the USA, developing strategic partnerships, and leveraging clinical data to drive early revenue opportunities. This approach is expected to unlock Neurotech’s potential and create value for shareholders and patients.
Neurotech International Ltd announced its participation in the NWR Virtual Healthcare Conference, where CEO Dr. Anthony Filippis will present. This event provides an opportunity for the company to showcase its advancements in pediatric neurological disorder treatments, particularly its NTI164 drug formulation, which has demonstrated significant therapeutic potential in clinical trials. The presentation is expected to enhance Neurotech’s visibility and potentially attract interest from investors and stakeholders in the biopharmaceutical sector.
Neurotech International Ltd. reported a significant financial loss for the half-year ending December 2024, with revenues from ordinary activities dropping to zero and a 922% increase in losses compared to the previous year. The substantial loss is largely attributed to increased research and development expenditures, highlighting the company’s ongoing investment in its core focus area despite the financial setback.
Neurotech International Ltd has received a positive opinion from the European Medicines Agency for Orphan Medicinal Product Designation of NTI164 for treating Rett Syndrome, a rare neurological disorder affecting approximately 28,000 females in Europe. This follows a similar designation by the US FDA, positioning NTI164 for market entry in both the US and Europe, potentially benefiting from regulatory advantages such as market exclusivity and fee reductions.
Neurotech International Ltd. announced a change in the director’s interest, revealing that Director Anthony Filippis, through Antfilippis Investments Pty Ltd, acquired 10 million NTIOPT28 and 10 million NTIOPT29 unlisted options. These options, set to mature in 2030, were acquired at no cost. This acquisition of options reflects strategic positioning within the company, potentially enhancing the director’s influence in company decisions and aligning interests with future company performance.
Neurotech International Ltd. announced the issuance of 20,000,000 unquoted options with varying exercise prices set for February 24, 2030. This issuance is part of previously announced transactions and is not intended for quotation on the ASX, potentially impacting the company’s financial strategy by providing additional equity-based incentives and aligning stakeholder interests.
Neurotech International Ltd has entered into a development agreement with RH Farma Dooel Skopje, a subsidiary of European Cannabis Company, to create a pharmaceutical-grade broad-spectrum cannabinoid drug product for pediatric neurodevelopmental disorders. This collaboration is intended to expand Neurotech’s market reach and enhance product quality using ECC’s expertise in cannabis-based product development and manufacturing. The agreement aligns with Neurotech’s strategic goal to meet global demand for high-quality cannabis-derived pharmaceuticals and further reinforces the company’s position in the industry.